BCM
RNAC icon

Bayesian Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Bayesian Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,476
Closed -$73K – 997
2022
Q3 		$73K Buy
+1,476
New +$81.1K 0.01% 615

Other funds holding RNAC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bayesian Capital Management's RNAC Position: Q4 2022 in Review

Bayesian Capital Management sold out of Cartesian Therapeutics (RNAC) in Q4 2022, closing a stake of 1,476 shares — an estimated $73K sold.

Bayesian Capital Management first reported a position in RNAC in Q3 2022 and held it in 1 quarter. The position peaked at $73K in Q3 2022. 84 funds tracked by Wall St. Rank hold RNAC as of Q4 2022.

  • Bayesian Capital Management reported no remaining Cartesian Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Bayesian Capital Management sold 1,476 Cartesian Therapeutics shares in Q4 2022, an estimated $73K.
  • Bayesian Capital Management first reported a position in Cartesian Therapeutics in Q3 2022 and held it in 1 quarter.
  • Bayesian Capital Management's Cartesian Therapeutics position peaked at $73K in Q3 2022.
  • 84 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2022.

Based on Bayesian Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.